A Clinical Study of Ifinatamab Deruxtecan Based Treatment Combinations or as Monotherapy to Treat Metastatic Castrate Resistant Prostate Cancer (mCRPC) (MK-2400-01A/IDeate-Prostate02)
Public ClinicalTrials.gov record NCT06863272. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
MK-2400-01A Substudy: A Phase 1/2, Open-label Umbrella Substudy of MK-2400-U01 Master Protocol to Evaluate the Safety and Efficacy of Ifinatamab Deruxtecan-based Treatment Combinations or Ifinatamab Deruxtecan Alone in Participants With Metastatic Castration-resistant Prostate Cancer (mCRPC) (IDeate-Prostate02)
Study identification
- NCT ID
- NCT06863272
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 1, Phase 2
- Lead sponsor
- Merck Sharp & Dohme LLC
- Industry
- Enrollment
- 360 participants
Conditions and interventions
Conditions
Interventions
- Abiraterone Drug
- Docetaxel Drug
- Enzalutamide Drug
- Ifinatamab Deruxtecan Drug
- MK-5684 Drug
- Rescue Medication Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 2, 2025
- Primary completion
- Mar 31, 2031
- Completion
- Mar 31, 2031
- Last update posted
- May 7, 2026
2025 – 2031
United States locations
- U.S. sites
- 7
- U.S. states
- 6
- U.S. cities
- 7
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| UCLA Hematology & Oncology ( Site 0003) | Los Angeles | California | 90095 | Recruiting |
| UCSF Medical Center at Mission Bay ( Site 0034) | San Francisco | California | 94158 | Recruiting |
| MedStar Georgetown Cancer Institute at MedStar Washington Hospital Center ( Site 0026) | Washington D.C. | District of Columbia | 20010 | Recruiting |
| Memorial Sloan Kettering Cancer Center ( Site 0006) | New York | New York | 10065 | Recruiting |
| UPMC Hillman Cancer Center ( Site 0014) | Pittsburgh | Pennsylvania | 15232 | Recruiting |
| The West Clinic, PLLC dba West Cancer Center ( Site 0005) | Germantown | Tennessee | 38138 | Recruiting |
| Fred Hutchinson Cancer Center ( Site 0013) | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 71 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06863272, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted May 7, 2026 · Synced May 9, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06863272 live on ClinicalTrials.gov.